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Background/Aims: Metabolic syndrome (MS) and its individual components are associated with nonalcoholic fatty liver disease (NAFLD) severity and progression. We sought to evaluate, in NAFLD patients discriminated by age, the effect of all components of the MS and of their combinations on the risk of severe hepatic fibrosis. 
Methods: We considered 863 consecutive biopsy-proven NAFLD patients, fully evaluated for components of MS – visceral obesity, IFG/diabetes, HDL, triglycerides and arterial hypertension. 
Results: At multivariate logistic regression analysis, severe fibrosis (F3-F4) was associated with visceral obesity (OR 20.5, 95%CI 2.29-235.9, p=0.01), IFG/diabetes (OR 2.66, 95%CI 1.76-4.04, p<0.001), and low HDL cholesterol (<40/<50 mg/dl; OR 1.73, 95%CI 1.17-2.56, p=0.006), but not triglycerides >150 or arterial hypertension. A significant interaction was found between age and visceral obesity (p=0.04). By stratifying patients for age, we confirmed the interaction between third tertile age (>54 years) and visceral obesity (p=0.04). Consistently, in the lower (<41 years) and middle (41-54 years) age tertiles, the risk for F3-F4 fibrosis was mostly driven by visceral obesity and IFG/diabetes, and was higher in those with all three metabolic risk factors (29% and 36% in lower and middle age tertiles, respectively). Finally, among patients in the higher age tertile (>54 years), obesity did not affect fibrosis severity, and the risk of severe fibrosis was higher in those with low HDL and IFG/Diabetes with/without visceral obesity (from 52% to 54%).
Conclusions: In NAFLD, among all components of MS, IFG/diabetes, low HDL and visceral obesity are the most closely associated with severe fibrosis. Metabolic profiles at risk for severe fibrosis changed according to age, with  low HDL, but mostly obesity and IFG/Diabetes being dominant in patients in lower and middle age tertiles, and HDL and IFG/Diabetes but not visceral obesity in those in the highest age tertile.

Introduction
The metabolic syndrome (MS) is a cluster of metabolic alterations that includes visceral obesity, high blood glucose, arterial hypertension, high triglycerides and low HDL levels, able to predict the occurrence of cardiometabolic events [1]. Nonalcoholic fatty liver disease (NAFLD) can be considered the hepatic counterpart of MS, and consistent with this, it shares with MS and its individual components a common pathogenic trigger, namely insulin resistance (IR) [2].
As expected, NAFLD and MS have a strong bidirectional interplay, with NAFLD being able to increase the risk of occurrence of MS and its components, and these in turn increasing the risk of NAFLD and of its severity.
Growing evidence from cohort studies has reported that the presence of NAFLD at baseline is an independent predictor of the occurrence of diabetes, hypertension, dyslipidaemia and MS [3-5], even if in some studies the association was lost after adjustment for IR [5]. On the other hand, in both Asiatic and Western large cohort studies, the presence of MS or of diabetes independently predicted the occurrence of fatty liver [6,7]. Consistent with all these data, while the prevalence of NAFLD in the general population is roughly 25%, it dramatically increases to over 50% in patients with MS or with its singular components [8].
When looking at the impact of MS and its components on the severity of fibrosis  the strongest predictor of hepatic and extrahepatic prognosis in NAFLD [9,10 ]-, contrasting evidence is available. Several studies, not always taking into account all MS components, has shown that obesity and/or diabetes and/or dyslipidemia are associated with NAFLD severity/progression [12-15], reporting however the impact on fibrosis of metabolic risk factors considered singularly, but not in combination. On the other hand, other studies, evaluating the number but not the kind of metabolic alteration, found that MS - defined as the presence of at least three metabolic alterations- was associated with severe fibrosis [8], and that the likelihood of a higher amount of liver fibrosis progressively increased according to the number of components of the MS [13]. Consistent with these data, American guidelines on diagnosis and management of NAFLD suggests that the presence of metabolic syndrome may be used for identifying patients who are at risk for steatohepatitis and advanced ﬁbrosis [11].




We analyzed data from 863 prospectively recruited NAFLD patients. The study cohort included 298 patients from the Gastrointestinal & Liver Unit of the Palermo University Hospital in Italy, 221 patients from the Westmead Millenium Institute, Sydney in Australia, 204 patients from the Metabolic Liver Diseases outpatient service, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, - Italy, and 140 patients from the Gastro-hepatology Division of the University Hospital Torino, Italy. Other causes of liver disease were ruled out, including alcohol intake (>20 g/day) evaluated by a questionnaire, viral and autoimmune hepatitis, hereditary hemochromatosis, and alpha1-antitrypsin deﬁciency. Patients with advanced cirrhosis, hepatocellular carcinoma, and current use of steatosis inducing drugs were excluded.
The study was carried out in accordance with the principles of the Helsinki Declaration, and with local and national laws. Approval was obtained from the hospital Internal Review Boards and their Ethics Committees, and written informed consent for the study was obtained from all controls and patients.
Clinical and Laboratory Assessment
Clinical and anthropometric data were collected at the time of liver biopsy. Body mass index (BMI) was calculated on the basis of weight in kilograms and height in meters; patients were classified as obese when BMI ≥30. Waist circumference (WC) was measured at the midpoint between the lower border of the rib cage and the iliac crest. Visceral obesity was defined according to ATPIII criteria (WC was >102 cm in males and > 88 cm in females) [16]. A diagnosis of arterial hypertension was based on the following criteria: systolic blood pressure ≥135 mm Hg and/or diastolic blood pressure ≥85 mm Hg (measured three times in 30 minutes, in the sitting position and using a brachial sphygmomanometer), or use of blood-pressure-lowering agents. A diagnosis of IFG/type 2 diabetes was based on the revised criteria of the American Diabetes Association, using a value of fasting blood glucose ≥100 for IFG and ≥126 mg/dL for diabetes on at least two occasions [17]. In patients with a previous diagnosis of type 2 diabetes, current therapy with insulin or oral hypoglycemic agents was documented. Metabolic syndrome was diagnosed according to ATPIII criteria [16]. 
Insulin resistance (IR) was determined according to the homeostasis model assessment (HOMA) method [18], as: Insulin resistance (HOMA-IR) = Fasting insulin (μU/mL) x Fasting glucose (mmol/L)/22.5.

Genetic Analyses
DNA was purified using the QIAmp blood Mini Kit (Qiagen, Mainz, Germany) and DNA samples were quantified using spectrophotometric determination. Genotyping for PNPLA3 (rs738409) was carried out using the TaqMan SNP genotyping allelic discrimination method (Applied Biosystems, Foster City, CA, USA). 
The genotyping call was done with SDS software v.1.3.0 (ABI Prism 7500, Foster City, CA, USA). Genotyping was conducted in a blinded fashion relative to patient characteristics.

Assessment of Histology
	Slides were coded and read at each clinical center by one expert pathologist, who was unaware of patients’ identity and history. The inter-observer agreement of pathologists between centers was acceptable [19] and similar to that reported in the literature [20]. A minimum 15mm-length of the biopsy specimen or the presence of at least 10 complete portal tracts was required [21]. Steatosis was assessed as the percentage of hepatocytes containing fat droplets (minimum 5%). The Kleiner classification [20] was used to compute steatosis, ballooning and lobular inflammation, and to stage fibrosis from 0 to 4. NASH was diagnosed in the presence of steatosis >5%, lobular inflammation and ballooning or fibrosis.
Statistical Analysis




The baseline features of the entire population of 863 NAFLD patients overall and split according to age tertiles are shown in Table 1.Mean age was 47 years, and 2 patients in three were males. Metabolic syndrome was present in 39% of cases, and 2 patients in three were obese. Diabetes was present in 41% of patients and arterial hypertension in 36%. About 37% and 35% of patients had high triglycerides and low HDL levels, respectively. Using the Kleiner criteria (39), one patient in five had fibrosis stage ≥ 3.

Effect of metabolic syndrome and its components on F3-F4 fibrosis
The prevalence of F3-F4 fibrosis progressively increased according to the number of metabolic alterations from 1.6% to 41.8% (Figure 1).Severe fibrosis was more prevalent in patients with IFG/diabetes (116/348, 33.3% vs 52/515, 10%; p<0.001), or visceral obesity (141/543, 25.9% vs 27/320, 8.4%; p<0.001), or HDL <40/50 mg/dl (80/301, 26.6% vs 88/562, 15.6%; p<0.001), or triglycerides >150 mg/dl, (75/322, 23.3% vs 93/541, 17.2%; p=0.02) or arterial hypertension (81/309, 26.2% vs 87/554, 15.8%; p<0.001) when compared with their counterparts.
When looking at the independent effect of each component of the MS on severe fibrosis, F3-F4 fibrosis remained significantly associated only with HDL mg/dl <40/50, visceral obesity and IFG/diabetes, together with older age, AST/ALT ratio and PLT values (Table 2 right). Conversely, female gender (OR 0.87, 95%CI 0.57-1.30, p=0.49), triglycerides >150 (OR 1.06, 95%CI 0.70-1.59, p=0.78) and arterial hypertension (OR 1.08, 95%CI 0.71-1.63, p=0.73) were not independently linked to F3-F4 fibrosis. Notably, we found a significant interaction between obesity and age (OR 0.95, 95%CI 0.91-0.99, p=0.04) (Table 2 right). 
To better explain this interaction, when we included in the model age stratified by tertiles instead of age as a continuous variable, we confirmed the independent link of visceral obesity (OR 3.54, 95%CI 1.35-11.1, p=0.01), IFG/diabetes (OR 2.78, 95%CI 1.83-4.26, p<0.001), and low HDL (OR 1.73, 95%CI 1.16-2.57, p=0.006) with F3-F4 fibrosis, but also observed a significant interaction of visceral obesity with the higher age tertile (OR 0.27, 95%CI 0.07-0.92, p=0.04) (Table 2 left).Consistent with these data, we generated different metabolic risk profiles for F3-F4 fibrosis based on low HDL cholesterol, IFG/diabetes and visceral obesity, stratified by age. Noteworthy, in patients in the lower age tertile (<41 years), the risk of F3-F4 fibrosis was negligible (<10%) in those without any of them or with one, low in those with two (from 11% to 19%) and moderate in those with all three metabolic risk factors (29%), with a greater weight of obesity and IFG/diabetes compared with HDL in terms of fibrosis risk (Figure 2A). Similarly, in the second age tertile (41-54 years), the risk for F3-F4 fibrosis was low in those without metabolic risk factors or with only one of them (from 3% to 11%), moderate in those with low HDL and visceral obesity or IFG/diabetes (from 13% to 17%), and moderate-high in those with IFG/diabetes and obesity with/without HDL<40/50 (from 25% to 36%) (Figure 2B). Finally, among patients in the higher age tertile (>54 years), we observed that obesity did not impact on the likelihood of F3-F4 fibrosis. The risk of severe fibrosis was moderate in those without metabolic risk factors or with only obesity (from 19% to 21%), moderate-high in those with only HDL<40/50 or IFG/Diabetes with/without obesity (from 29% to 42%), and very high in those with HDL<40/50 and IFG/Diabetes with/without obesity (from 52% to 55%) (Figure 2C). Bootstrap procedure showed no significant differences between the bootstrapped coefficient estimates and the model coefficients (estimated model bias range : -0.100  – 0.088, corresponding to a range of bootstrap p-values range of 0.8908 to 0.9754 and 9997, see supplementary table 1); bootstrapped model p-values are substantially similar to the original p-value, the biggest difference being 0.022 , so that all significant variables in the model are also significant in the bootstrapped model. Corrected Somer's D index between predicted probability and observed responses is 0.593, which corresponds to an AUC of 0.797, showing a moderately good predictive performance of the model.
	Due to the strong correlation of low HDL cholesterol, IFG/Diabetes and visceral obesity with insulin resistance, we also included in the model HOMA as an independent variable. As expected, we found that HOMA (OR 1.07, 95%CI 1.02-1.13, p=0.006) was independently associated with F3-F4 fibrosis, also confirming the independent association of this with obesity (OR 3.60, 95%CI 1.25-13.0, p=0.02), IFG/diabetes (OR 2.09, 95%CI 1.29-3.42, p=0.003), and low HDL cholesterol (OR 1.55, 95%CI 1.01-2.40, p=0.04), as well as the significant interaction between age >54 years and obesity (OR 0.20, 95%CI 0.04-0.80, p=0.02). However, neither the estimated effects size, nor the significance structure of the parameter was substantially altered. In addition, the predictive performance of the two models was nearly equal (AUC = 0.815  with HOMA vs AUC = 0.804  without, p=0.69).




In this study of 863 patients with a histological diagnosis of NAFLD, and characterized for all components of the MS, we found that IFG/diabetes, low HDL and visceral obesity, but not high triglycerides and arterial hypertension, were independent risk factors for severe liver fibrosis. When discriminating patients according to classes of age, the risk for severe fibrosis was driven by low HDL and mostly by IFG/Diabetes and obesity in patients in the lower and middle age tertiles, with the higher risk observed in patients with all three metabolic risk factors. Conversely, IFG/diabetes and low HDL, not visceral obesity, were the main predictors of severe fibrosis in patients in the older age tertile. Notably these results were further confirmed after correction for genetic, biochemical and metabolic-HOMA- risk factors for fibrosis.
Metabolic alterations share similar pathogenic triggers like IR, and as expected in the same individual, different metabolic disturbances can coexist, together contributing to liver damage. MS has been associated with severe fibrosis [8], and the higher the number MS components, the greater   the severity of fibrosis [13]. Consistent with these data obesity, diabetes, dyslipidemia and hypertension have also been associated with NAFLD severity/progression [12-15]. However, these studies took into account the number of metabolic risk factors or the effect of a singular risk factor but not the age-dependent quantitative and qualitative impact of their combinations.
In our study, we confirmed that the prevalence of severe fibrosis increased according to the number of metabolic features. However, a more critical analysis allowed us to confirm the association of only visceral obesity, IFG/diabetes and low HDL cholesterol with the severity of hepatic fibrosis. Notably, this feature was obtained by considering together all the components of the metabolic syndrome and after adjusting for age, gender and biochemical markers of liver fibrosis, and was further confirmed by correcting for PNPLA3 genotype. In this manner we identified the independent weight of each metabolic alteration as a risk factor for severe fibrosis in NAFLD. 
The most relevant finding of our study lies in the assessment of the impact of different metabolic profiles on the severity of fibrosis according to classes of age. Notably, we found that among patients in the lower and middle age tertiles, the risk for severe fibrosis was driven by low HDL and mostly by visceral obesity and IFG/diabetes, with the higher risk in patients with all three metabolic alterations. Conversely, among patients in the higher age tertile the risk was mainly driven by both HDL and IFG/Diabetes, with the higher risk in those with this association and without impact of obesity. Noteworthy, internal validation of these results make us confident on their robustness.
The lack of effect of obesity on the severity of fibrosis in older patients is difficult to explain even if some hypotheses can be entertained Obesity is a principal determinant of NAFLD and its progression [22]. However, it should be possible that in older patients the impact of obesity-related metabolic alterations like diabetes and atherogenic dyslipidemia overcomes obesity per se. In addition, recent evidence assessing the impact of obesity on mortality and cardiovascular outcomes suggests that aging can attenuate the association between high BMI and poor outcomes [23,24]. Besides, the higher weight of low HDL on severe fibrosis in older patients could be the expression of a more severe diabetes and age-related atherogenic dyslipidemia phenotype.
In our study we did not find an independent association between arterial hypertension and severity of fibrosis, while a recent meta-analysis identified hypertension as a risk factor for fast fibrosis progression in NAFLD [25]. Differences in assessed outcomes (fibrosis severity vs fibrosis progression), and the lack of individual patient data in the meta-analysis, could explain the discrepancies in the results.
The main limitation of this study is the cross-sectional design that makes us unable to definitively ascertain the temporal relationship between metabolic alterations and the severity of fibrosis in NAFLD. A further methodological question is the potentially limited external validity of the results for different populations and settings. Our study included a cohort of Caucasian patients enrolled at tertiary care centers, who may be different in terms of both metabolic features and severity of liver disease, from the majority of prevalent cases of NAFLD in the general population. In spite of these limits, strengths of this study are internal validation and the large sample size, that allowed us to stratify patients according to metabolic profiles and classes of age.
From a clinical point of view our study suggests that in patients with NAFLD, while all components of MS should be assessed for the evaluation of cardiovascular risk, considering the assessment of liver damage, the presence of IFG/diabetes, visceral obesity and low HDL, considered alone and in combinations allows oneto identify age-dependent metabolic profiles at different risk for severe liver fibrosis. Notably, the ability of prediction by our model did not change when considering also HOMA, an expression of IR, suggesting that the assessment of a not widely available parameter like insulin does not add a significant advantage in the prediction of the risk of fibrosis when added to classical MS components. However, the lack of OGIS ─an expression of peripheral IR and predicting severe fibrosis better than HOMA [26]─ could affect the interpretation of these results.
In conclusion, this study on a large cohort of patients with a histological diagnosis of NAFLD demonstrated that among all components of MS, IFG/diabetes, low HDL and visceral obesity are those mostly associated with the severity of fibrosis. Notably, metabolic profiles at risk for severe fibrosis changed according to age, with low HDL and mostly both obesity and IFG/Diabetes being dominant in patients in the lower and middle age tertiles, while low HDL cholesterol and IFG/Diabetes but not visceral obesity in those in the higher age tertile.

Legends
Figure 1. Prevalence of F3-F4 fibrosis according to the number of metabolic alterations in the entire NAFLD cohort. 
Figure 2. Prevalence of F3-F4 fibrosis according to the number of metabolic alterations in the NAFLD cohort according to tertiles of age. A. NAFLD patients in the lower quartile of age (<38 years); B. NAFLD patients in the middle quartiles of age (38-57 years); C. NAFLD patients in the higher quartile of age (>57 years). I am confused different ages cuts to the rest of manuscript and also here it is qquartiles?????
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